Other

Swiss drug maker Roche posts flat 3Q sales

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

Oncology & Cancer

Disappointment as breast cancer drug not approved on NHS

The breast cancer drug trastuzumab emtansine (also known as Kadcyla) will not be made routinely available on the NHS following a failure to reach an agreement on price between the National Institute for Health and Care Excellence ...

Medications

Roche buying Seragon in US for up to $1.7 billion

Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.

Oncology & Cancer

US OKs first-ever DNA alternative to Pap smear (Update 2)

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

Medications

EU regulator: No more problems with Roche drugs

The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.

Oncology & Cancer

FDA approves leukemia drug from Roche

The Food and Drug Administration has approved a new drug from Roche to help treat patients with a type of cancer of the blood and bone marrow.

page 4 from 7